๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangdong
Clinical trial register · China

Clinical Trials in Guangdong, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University9 AstraZeneca3 Eli Lilly and Company3 Zhongshan Ophthalmic Center, Sun Yat-sen University3 Second Affiliated Hospital, Zhejiang University, School of Medicine3
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Guangdong

71 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
NCT07613359Antibody-Mediated Rejection (AMR)
DrugMezagitamab
Takeda
Phase 2
36
Beijing, Guangdong, Nanning, Wuhan, Xi'an, Jinan, Chengdu, Hangzhou
2026-09-01
Not yet open
Universal STAR-T Cell Injection in Autoimmune Kidney Diseases
NCT07746453IgA Nephropathy (IgAN), Primary Membranous Nephropathy
Guangdong Provincial People's Hospital
Not applicable
24
Guangdong
2026-08-31
Not yet open
Cohort Study on Refractive Errors in Preschool Children
NCT07706218Refractive Errors
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
1,000
Guangdong
2026-08-01
Not yet open
An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
NCT07709533Valid MeSH Conditions
DrugsPaclitaxel·Cisplatin
Sun Yat-sen University
Phase 2
347
Guangdong
2026-07-07
Not yet open
Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia
NCT07612605Pneumonia
DrugBacteriophage
Chinese PLA General Hospital
Phase EARLY_PHASE1
250
Guangdong, Beijing
2026-06-01
Recruiting
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
NCT07610720Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast Cancer
Sun Yat-sen University
Phase 2
57
Guangdong
2026-06-01
Recruiting
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
NCT07548177Alveolar Soft Part Sarcoma
DrugsAnlotinib hydrochloride·Benmelstobart
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
33
Beijing, Chongqing, Guangdong, Harbin, Zhengzhou, Wuhan, Changsha, Changchun
2026-04-02
Recruiting
A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity
NCT07478822Upper Limb Spasticity
DrugRecombinant Botulinum Toxin Type A
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 3
300
Beijing, Chengdu, Guangdong, Guangzhou, Hefei, Huai'an, Kaifeng, Kunming
2026-03-27
Recruiting
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
NCT07493265Narcolepsy
DrugE2086
Eisai Inc.
Phase 2
64
Beijing, Changchun, Guangdong, Guangzhou, Jinan, Nanchang, Shanghai, Zhengzhou
2026-03-26
Recruiting
Deep Cervical Lymphatic Venous Anastomosis in the Treatment of Alzheimer's Disease (CLEAN-AD)
NCT07073066Alzheimers Disease
Beijing Tiantan Hospital
Not applicable
376
Dongguan, Guangdong, Zhengzhou, Jinan, Jining, Ningbo, Beijing
2026-03-13
Recruiting
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
DrugsIdelalisib·Pirtobrutinib
Eli Lilly and Company
Phase 4
150
Beijing, Changsha, Guangdong, Guangzhou, Lanzhou, Nanchang, Shanghai, Taizhou
2026-03-09
Not yet open
Effect of Different Needle Insertion Positions on the Clinical Outcomes of YAMANE Technique
NCT07446829Congenital Ectopia Lentis
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
54
Guangdong
2026-02-28
Recruiting
Efficacy of Montelukast on STEMl Patients
NCT07320625Myocardial Infarction (MI)
DrugMontelukast
Shanghai Zhongshan Hospital
Phase 3
512
Dalian, Shanghai, Fuzhou, Guangdong, Haโ€™erbin, Hefei, Hunan, Shenyang
2026-02-01
Not yet open
Dexamethasone Regimens for BPD Prevention in Preterm Infants
NCT07052201Infant, Premature, Bronchopulmonary Dysplasia (BPD)
The Children's Hospital of Zhejiang University School of Medicine
Phase 3
970
Hangzhou, Chengdu, Chongqing, Guangdong, Guangxi, Guiyang, Guizhou, Jilin City
2026-02-01
Active, closed
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
NCT07341100Ovarian Epithelial Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
20
Guangdong
2026-01-16
Not yet open
Effect of Intrathecal Morphine on Quality of Recovery After Laparoscopic Gynecological Surgery
NCT07322029Laparoscopic Gynecological Surgery
Sun Yat-sen University
Not applicable
252
Guangdong
2026-01
Not yet open
Influence of Different Needle Insertion Positions on the Clinical Efficacy of Suture-Fixated Transscleral IOL Implantation Without Knots
NCT07252349Congenital Ectopia Lentis
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
54
Guangdong
2025-12-25
Active, closed
Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT07374003Locally Advanced, Resectable
Sun Yat-sen University
Phase 2
62
Guangdong
2025-12-17
Recruiting
Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07371234Locally Advanced Head and Neck Squamous Cell Carcinoma
DrugAdjuvant Cisplatin
Rui You
Phase 2
22
Guangdong
2025-12-15
Recruiting
Preoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound
NCT07357571Thyroid Papillary Carcinoma, Contrast Enhanced Ultrasound
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
600
Guangdong, Guangzhou
2025-12-01
Recruiting
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
NCT07328841Nasopharyngeal Carcinoma (NPC)
Ming-Yuan Chen
Phase 3
456
Guangzhou, Shantou, Zhongshan, Nanning, Wuzhou, Wuhan, Changsha, Guangdong
2025-11-18
Recruiting
TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage
NCT07187687Intracerebral Hemorrhage
Xuanwu Hospital, Beijing
Not applicable
750
Guangdong, Baotou, Beijing, Bozhou, Changsha, Changzhi, Changzhou, Chifeng
2025-10-24
Recruiting
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
NCT07101744Nasopharyngeal Carcinoma (NPC), First-line Treatment Failure Nasopharyngeal Carcinoma
DrugIparomlimab and Tuvonralimab
Sun Yat-sen University
Phase 2
41
Guangdong
2025-10-17
Recruiting
TCM as an Adjuvant Treatment in Mycobacterium Abscessus Pulmonary Disease
NCT07295938Mycobacterium Abscessus Pulmonary Disease
Shanghai University of Traditional Chinese Medicine
Phase 2
352
Beijing, Guangdong, Hefei, Nanchang, Shanghai
2025-09-08
By invitation
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
NCT07376629TNBC
DrugsHB0025·Nab-paclitaxel
Huabo Biopharm Co., Ltd.
Phase 2
60
Anyang, Changsha, Chengdu, Fujian, Guangdong, Guangzhou, Hangzhou, Harbin
2025-08-14
Recruiting
China Colorectal Cancer Screening Trial 1 (C-Cost1)
NCT07090291Colorectal Cancer, Advanced Adenoma
Zhejiang University
Not applicable
60,300
Guandong, Guangdong, Hebei, Nanjing, Shanghai, Sichuan, Zhejiang
2025-08-08
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugRopeginterferon alfa-2b
PharmaEssentia
Phase 3
160
Beijing, Chongqing, Guangdong, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing
2025-07-18
Recruiting
A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors
NCT07043751Advanced Malignant Tumors
DrugTQB6411
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
216
Beijing, Dongguan, Guangdong, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha
2025-07-15
Recruiting
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
NCT06924606Advanced NSCLC
DrugsJS004·JS207·Docetaxel
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
66
Beijing, Jilin City, Hunan, Sichuan, Chongqing, Guangdong, Heilongjiang, Anyang
2025-07-15
Recruiting
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
NCT06862206Chronic Obstructive Pulmonary Disease
AstraZeneca
Observational
1,000
Anhui, Anning, Beijing, Binzhou, Changzhou, Fenyang, Guangdong, Guangzhou
2025-07-11
By invitation
Supraglottic Jet Oxygenation Ventilation During Hysteroscopic Surgery
NCT07110428Hysteroscopic Surgery
Peking University Shenzhen Hospital
Not applicable
100
Guangdong
2025-07-03
Recruiting
Evidence-based Practice in the Management of Gastric Tube Placement in Children
NCT07038538Hospitalized Children, Nursing, Enteral Nutrition Therapy
Children's Hospital of Fudan University
Not applicable
2,750
Shanghai, Beijing, Chongqing, Gansu, Guangdong, Hefei, Henan, Hunan
2025-06-26
Recruiting
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
NCT06764615Crohn's Disease, Ulcerative Colitis
DrugZasocitinib
Takeda
Phase 2
192
Chongqing, Guangdong, Guangzhou, Shanghai
2025-05-28
Recruiting
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy๏ผˆFIRMOST๏ผ‰
NCT07010419NSCLC, Adjuvant Treatment
DrugFurmonertinib
Allist Pharmaceuticals, Inc.
Phase 3
338
Beijing, Guangdong
2025-05-28
Recruiting
Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in Children
NCT07188311Hepatoblastoma, Pediatric Cancer
Sun Yat-sen University
Not applicable
24
Guangdong
2025-04-10
Recruiting
Tubeless Tracheal and Carinal Reconstruction
NCT07065565Tracheal Disease, Airway Disease
Shuben Li
Not applicable
176
Guangdong
2025-03-26
Recruiting
Lecanemab for Early Onset Familial Alzheimer's Disease
NCT06883019Alzheimer Disease
RenJi Hospital
Observational
114
Beijing, Guangdong, Guizhou, Jiangsu, Shanghai, Sichuan, Tianjin, Zhejiang
2025-03-13
Recruiting
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
NCT06832982Advanced Solid Tumors
Shanghai Pushi Medical Science Co. Ltd
Phase 1
66
Beijing, Fujian, Zhejiang, Heilongjiang, Shandong, Guangdong, Shenyang, Hebei
2025-02-24
Recruiting
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
NCT06809764Non-small Cell Lung Cancer
Daiichi Sankyo
Observational
150
Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei
2025-02-21
Recruiting
A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
NCT06820268B-cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome
NovaOnco Therapeutics Co., Ltd.
Phase 1
168
Beijing, Guangdong, Hebei, Hubei
2025-01-14
Recruiting
Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)
NCT06734832Hand, Foot, and Mouth Disease๏ผˆHFMD)
Sinovac Biotech Co., Ltd
Phase 3
8,000
Hefei, Fujian, Guangdong, Hubei
2024-12-13
Recruiting
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
NCT06970639NSCLC Patients With Brain Metastasis
DrugsFurmonertinib Mesilate·Pemetrexed Disodium·Osimertinib·Cisplatin
Allist Pharmaceuticals, Inc.
Phase 3
380
Guangdong
2024-09-26
Active, closed
Onco-Respirology Epidemiology Based on Real-world Big Data in Respiratory Medicine
NCT06670560Respiratory, Epidemiology, Neoplasms
Zhou Chengzhi
Observational
100,000
Guangdong
2024-09-05
Recruiting
Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.
NCT06597201End Stage Renal Disease (ESRD)
DrugAmino acid (15) peritoneal dialysis
Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Phase 4
400
Hefei, Beijing, Wuhan, Changsha, Chengdu, Chongqing, Ganzhou, Guangdong
2024-08-09
Active, closed
Efficacy of PD-1 Monoclonal Antibody in the Treatment of Phaeohyphomycosis
NCT06796231Phaeohyphomycosis
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
1
Guangdong
2024-07-12
Recruiting
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
NCT06390306Chronic Myeloid Leukemia
DrugsPonatinib·Olverembatinib·Azacitidine·Venetoclax
Peking University People's Hospital
Observational
30
Beijing, Chengdu, Guangdong, Kunming, Nanjing, Nanning, Nanyang, Ningbo
2024-07-01
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
DrugLY3650150
Eli Lilly and Company
Phase 3
510
Beijing, Bengbu, Changsha, Chengdu, Foshan, Fuzhou, Guangdong, Haikou
2024-04-29
Recruiting
A Study of HLX42 in Advanced/Metastatic Solid Tumors
NCT06210815Solid Tumor and NSCLC
Shanghai Henlius Biotech
Phase 1
102
Guangdong
2024-03-14
Active, closed
FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery Disease
NCT06218485Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,942
Beijing, Changsha, Chongqing, Ganzhou, Guangdong, Hangzhou, Huzhou, Jinan
2024-03-13
Active, closed
A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients
NCT06099236Atypical Hemolytic Uremic Syndrome(aHUS)
AstraZeneca
Observational
367
Beijing, Chongqing, Anhui, Fujian, Guangdong, Guangxi, Guizhou, Hainan
2024-01-15
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Bengbu, Chongqing, Guangdong, Zhengzhou, Wuhan, Suzhou, Shanghai, Chengdu
2023-08-31
Recruiting
Safety and Effectiveness of TaurusTrioโ„ข Heart Valve System in Patients With Severe Aortic Regurgitation (AR)
NCT06101888Aortic Regurgitation
Peijia Medical Technology (Suzhou) Co., Ltd.
Not applicable
116
Beijing, Fuzhou, Xiamen, Guangzhou, Guangdong, Haerbin, Wuhan, Changsha
2023-08-01
Recruiting
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
NCT05909332Breast Cancer, Triple Negative Breast Cancer
Fudan University
Phase 3
764
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-20
Recruiting
Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
NCT05794971Colorectal Cancer Liver Metastases, Regorafenib
DrugRegorafenib
Sun Yat-sen University
Phase 3
126
Guangdong
2023-06-10
Recruiting
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
NCT05891093Breast Cancer
DrugsTamoxifen·Fluzoparib·Anastrozole·Exemestane
Fudan University
Phase 3
766
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-01
Recruiting
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases
NCT05768490Brain Metastases, Radiotherapy, EGFR Activating Mutation
DrugAlmonertinib
Sun Yat-sen University
Phase 3
232
Guangdong
2023-03-15
Recruiting
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
DrugsVepugratinib·Digoxin·Rosuvastatin·Enfortumab Vedotin
Eli Lilly and Company
Phase 1
677
Beijing, Guangdong, Hangzhou, Shanghai, Tianjin, Xi'an, Zhejiang
2023-01-12
Recruiting
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
NCT05461768Breast Cancer, Locally Advanced or Metastatic Solid Tumor
DrugBL-M07D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
348
Fuzhou, Dongguan, Guangdong, Zhengzhou, Wuhan, Jinan, Hangzhou
2022-08-09
Active, closed
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
NCT05426733Biliary Atresia
DrugOdevixibat
Albireo, an Ipsen Company
Phase 3
180
Guangdong, Shanghai
2022-07-05
Active, closed
NAC for Treatment-Resistant OCD and Other Related Disorders
NCT06956157Obsessive Compulsive Disorder (OCD)
Guangdong Provincial People's Hospital
Phase 4
90
GuangDong
2022-06-22
Active, closed
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
NCT05280470Extensive-stage Small-cell Lung Cancer
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 2
187
Changchun, Changsha, Chengdu, Guangdong, Hangzhou, Linyi, Shanghai, Wuhan
2022-03-09
Active, closed
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
NCT05020769Non-small Cell Lung Cancer
DrugsSI-B001·Osimertinib
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
14
Guangzhou, Guilin, Guangdong
2022-01-06
Active, closed
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
NCT05070858Generalized Myasthenia Gravis
DrugsCemdisiran·Pozelimab
Regeneron Pharmaceuticals
Phase 3
288
Beijing, Fuzhou, Guangdong, Guangzhou, Shenzhen, Haikou, Wuhan, Changsha
2021-12-14
Active, closed
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
NCT05043922Ovarian Cancer, Recurrent Cancer
DrugCYH33
Haihe Biopharma Co., Ltd.
Phase 2
93
Beijing, Chongqing, Guangdong, Haikou, Hainan, Hangzhou, Harbin, Hubei
2021-10-11
Active, closed
Phacotrabeculectomy Versus Phacogoniotomy (PVP) in Advanced Primary Angle-closure Glaucoma
NCT04878458Glaucoma, Angle-Closure
Sun Yat-sen University
Not applicable
124
Guangzhou, Guangdong
2021-05-31
Recruiting
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
NCT04685226Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
310
Hefei, Beijing, Guangzhou, Zhuhai, Guangdong, Shijiazhuang, Harbin, Luoyang
2020-09-27
Recruiting
Chinese Psoriasis Real World Evidence Research
NCT04465838Psoriasis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Hangzhou, Beijing, Chongqing, Fujian, Gansu, Guangdong, Guangxi, Guizhou
2020-07-08
Active, closed
Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease
NCT04397211Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,872
Hangzhou, Beijing, Guangdong, Huzhou, Jinan, Jinhua, Kunming, Nanchang
2020-05-29
Active, closed
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04269200Endometrial Neoplasms
DrugsOlaparib·Durvalumab·Paclitaxel·Carboplatin
AstraZeneca
Phase 3
805
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangdong, Guangzhou
2020-05-05
Recruiting
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
NCT04192344Neoplasms, Tenosynovial Giant Cell Tumor
DrugPimicotinib
Abbisko Therapeutics Co, Ltd
Phase 1
276
Beijing, Guangdong, Shijiazhuang, Zhengzhou, Nanjing, Shenyang, Shanghai, Xian
2020-01-20
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsZolbetuximab·Nab-paclitaxel·Gemcitabine
Astellas Pharma Global Development, Inc.
Phase 2
393
Beijing, Changchun, Chongqing, Guangdong, Guangzhou, Harbin, Hubei, Jiangsu
2019-03-15
Rows per page Showing 1–71 of 71
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangdong

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 71 of those studies with a site in Guangdong.

How many clinical trials are recruiting in Guangdong?

43 of the 71 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 9 have not yet opened recruitment, 17 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangdong), 71 studies
PhaseStudiesRecruitingShare
Phase 3171223.9%
Phase 216822.5%
Not applicable15721.1%
Observational10614.1%
Phase 1779.9%
Phase 4324.2%
Phase 1/2111.4%
Phase 2/3101.4%
Phase EARLY_PHASE1101.4%

Most active sponsors

Lead sponsors with the most studies (Guangdong)
Lead sponsorStudiesRecruiting
Sun Yat-sen University95
AstraZeneca31
Eli Lilly and Company33
Second Affiliated Hospital, Zhejiang University, School of Medicine31
Zhongshan Ophthalmic Center, Sun Yat-sen University30
Allist Pharmaceuticals, Inc.22
Daiichi Sankyo21
Fudan University22
Guangdong Provincial People's Hospital20
Sichuan Baili Pharmaceutical Co., Ltd.21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.